HERENTALS, Belgium -- Kemin Pharma announces the identification of novel, carbohydrate-based molecules with highly effective and selective activity against human cytomegalovirus (CMV).
"In our initial in vitro screening, a new molecule, identified as KPE1015, was nearly as effective as the positive control, ganciclovir, the only antiviral treatment currently available against CMV. We were able to chemically modify and optimize this lead molecule, creating molecule KPE1116, which delivered improved in vitro activity, superior to ganciclovir, against both the Davis and AD-169 strains of CMV," says Dr. Benedikt Sas, general manager of Kemin Pharma.
These molecules are part of a new class of molecules being screened by Kemin Pharma that exhibit very promising activity, selectivity and toxicity profiles. Sas says, "Our research is focused on complete, novel molecules with three dimensional structures, several chiral centers and new modes of action. There are few pharmaceutical compounds with chiral centers, because most are flat molecules."
An effective treatment for CMV infections is especially significant for immunodeficient patients, including AIDS patients, patients receiving chemotherapy, organ transplant recipients and pregnant women. CMV infection can cause a number of symptoms including retinitis, viral pneumonia, colitis, hepatitis, encephalitis and mononucleosis.
"We are excited about this promising new molecule. The current available treatment for CMV has a number of undesirable side effects including reduction in white blood cells, kidney damage, nausea, vomiting, diarrhea and rash. Plus, studies and surveillance data are showing an ever-increasing level of CMV resistance to the treatment," Sas added.
Kemin Pharma was established in January 2001 as a wholly owned, independent subsidiary of Kemin Industries, Inc. Its mission is to develop new, unique, antimicrobial compounds effective against bacteria, viruses and fungi, as well as protozoa, which present a serious, unmet medical challenge throughout the world. Kemin Pharma's screening efforts are focused on compounds that are likely to have a higher success rate, a strategy that has been very successful for the company. In the first two years of its existence, Kemin Pharma researchers have isolated and are currently conducting preclinical trials on six compounds and are conducting Phase II clinical trials on another compound.
Source: Kemin Pharma
Dear Helpdesk: Working in a Toxic Health Care Environment
March 28th 2024Dear Helpdesk is your steadfast companion, offering life coaching and workplace advice from 2 seasoned IPs for some of your most challenging real-life situations. Let us help you navigate the intersection between work and life, guiding you to navigate the dynamic world of infection prevention with confidence and grace. This article is on handling a toxic health care environment.
Product Locator: Spring and Early Mother's Day Gift Guide for Infection Prevention Personnel
March 27th 2024Whether it's a spring holiday, birthdays, or no reason at all, infection prevention personnel love to give and receive gifts that help at the end of a stressful day. Infection Control Today® offers some gift ideas for infection prevention personnel and their families.
Catching Up With Vangie Dennis, AORN 2022-2023 President at AORN 2024
March 26th 2024Infection Control Today (ICT) had the privilege of catching up with Vangie Dennis, MSN, RN, CNOR, CMLSO, at the Association of periOperative Registered Nurses' (AORN’s) International Surgical Conference & Expo 2024. As the former president of AORN and an esteemed figure in perioperative services, Vangie Dennis shared insights into her recent endeavors and the exciting new chapter she's embarked upon.
How To Optimize Your Time Management Strategies for the Busy Infection Preventionist
March 25th 2024Is your calendar resembling a chaotic masterpiece of overlapping tasks? Join the club of infection preventionists striving to balance responsibilities. Dive into proven strategies from a fellow infection preventionist to reclaim control of your time, streamline tasks, and boost productivity effectively. This is an IP Lifeline article.